Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05028894 · ClinicalTrials.gov registry record
23andMe IPF Research Study
A clinical trial, sponsored by 23andMe.
- Completed
- Registry status
- 690
- Enrollment target
NCT05028894: Completed study, sponsored by 23andMe.
NCT05028894 is a clinical trial that has completed, run by 23andMe. The registered enrollment target is 690 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05028894 has completed, sponsored by 23andMe.
- COMPLETED
- Registry status
- 690 participants
- Enrollment target
Study Summary
The long term goal of this study is to increase genetic understanding of IPF to enable the development of an effective drug for IPF that can improve the lives of those living with the condition.
Primary Outcome
Survey asking about disease diagnosis, testing, treatments, and symptom progression
Interventions
- OTHER No intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 690 participants |
| Start Date | 2020-06-05 |
| Est. Completion | 2023-05-05 |
What the finished NCT05028894 record still lists
NCT05028894 is an observational study that tracks outcomes without assigning an intervention. The registered 690 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which No intervention is the first listed.
NCT05028894 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05028894 about?
NCT05028894 is a clinical study titled "23andMe IPF Research Study". The long term goal of this study is to increase genetic understanding of IPF to enable the development of an effective drug for IPF that can improve the lives of those living with the condition.
What is the current status of trial NCT05028894?
This trial is currently completed. The enrollment target is 690 participants. The study started on 2020-06-05. Estimated completion is 2023-05-05.
What interventions are being tested in trial NCT05028894?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT05028894?
This trial is sponsored by 23andMe, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00532051 · 690 participants
Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence Tomography
- NCT05184335 · 690 participants · Phase 3
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
- NCT07221149 · 690 participants · Phase 2
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- NCT07382167 · 692 participants · Phase 3
A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI